# NCT05379985 (NCT05379985)

> Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05379985
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors
- Interventions: RMC-6236
- Enrollment: 754
- Primary outcome: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
- Primary outcome: Number of Participants with Dose-Limiting Toxicity (DLT)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05379985